Delivery Order SPE2DB20D3103-SPE2DB25FN5G5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL vials, with a ceiling value of $1,566.65. This is a firm fixed-price delivery order with no set-aside designation, placed under competitive award procedures. The contract is set to be completed by September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,621.17 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3ml quantities. This competitively awarded, firm fixed-price delivery order is set to be completed by August 29, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations, with a ceiling value of $2,015.92. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,095.18 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3ml volumes. This firm fixed-price delivery order, issued on June 30, 2025, with completion targeted for July 1, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract carries no set-aside designation and was competitively awarded....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 14, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL vials, with a ceiling value of $14,744.31. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations, with a contract ceiling value of $25,162.48. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this qualified vendor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 ml vials, with a contract ceiling value of $43,208.69. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a routine pharmaceutical procurement under a competitively awarded, non-set-aside contract vehicle. The work will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $4,361.80 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitive award uses firm fixed pricing with no set-aside designation and is scheduled for completion by August 12, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for Ozempic (0.25-0.5 mg/dose) pens in 3ml quantities, valued at $5,043.18. This is a firm fixed-price delivery order with an ultimate completion date of June 2, 2025, representing a non-competitive set-aside award. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations, with a ceiling value of $5,351.12. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of July 23, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FN5G5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations, with a ceiling value of $8,761.83. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.9 billion through December 2026. The award was made through competitive procedures with no set-aside designation, utilizing firm fixed-price pricing terms. Performance will be completed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of April 23, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. As the prime contractor on this delivery order, the company supplies a comprehensive range of pharmaceutical products to the Defense Health Agency and other federal healthcare customers. This specific order for Ozempic, a diabetes medication, exemplifies the company's role in fulfilling therapeutic pharmaceutical needs across the federal healthcare enterprise through the DLA's global pharmaceutical support infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 4/22/25 |